MMHC WELCOMES NEW CEO

Medically Minded, Inc. (OTC Pink: MMHC) Progress Update

ST. THOMAS, U.S. VIRGIN ISLANDS -- April 20, 2016 -- InvestorsHub NewsWire -- Medically Minded, Inc. (OTC PINK: MMHC), in an effort to keep shareholders informed of its current activity, announced the following update:

Our filings due for the period ended December 31, 2015 have been filed with OTC Markets as of April 19, 2016. We expect to return to Current Information status over the next day or two and are actively working on the upcoming filing for the period ended March 31, 2016 so as to assure it is filed within the required deadline.

The Company recently announced it would recruit individuals to oversee the Company’s CBD division as well as its corporate filing and governance of being a publicly-traded company. As part of that process, the Company has retained James Grady to act as CEO of Medically Minded, Inc. and guide the Medically Minded International subsidiary forward towards product acquisition and sales. Mr. Grady brings over 25 years of professional sales experience to the Company, new business development, sales management, and marketing. Additionally, Mr. Grady brings the following resources and skills to Medically Minded:

Managed total revenues of over $85.5 million
Negotiated business accounts with various suppliers and vendors to ensure the highest quality at the most competitive prices.
Trained and managed anywhere from 12 to 50+ employees in their respective areas: sales, front office management, customer service, product service and CRM (ACT). Established written monthly sales goals to meet or exceed financial objectives. Continuously conducted sales and customer service training in order to maintain the highest standards set forth.
Developed successful advertising and marketing plans by branding company name and reputation and by also increasing on-line presence via internet marketing, all of which dramatically increased sales.
Established company budgets, prepared and analyzed financial statements, and supervised accounting matters in order to constantly improve the company’s financial position.
Negotiated with lenders in order to secure the most competitive financing rates and terms.
Reviewed product pricing and gross margin goals for existing products annually and established new product pricing in order to maintain acceptable margins.

The retaining of Mr. Grady is a step in the Company’s plan to focus on areas of the medical marijuana and CBD Hemp markets that provide the opportunity for immediate revenues. As part of this model it was decided that the Company would no longer support Medically Minded, U.S.V.I. (“MMUSVI”) activity in the U.S. Virgin Islands and therefore has divested of that subsidiary. It is believed that efforts would be better served in the development/marketing of CBD Hemp products and securing opportunities in States where medical marijuana has already been legalized. Mr. Steven Jones will continue move MMUSVI’s operations in the Islands forward and step down as CEO of the Company.

Mr. Grady and Mr. Ken Sobel, acting President, are working to finalize Mr. Sobel’s arrangement, role, duties and responsibilities. The Company considers Mr. Sobel and the opportunities he provides as a key resource to its business model. Mr. Grady has made Mr. Sobel’s involvement and activity on behalf of the Company one of his top priorities as things progress. It is the Company’s agenda to work with Mr. Sobel on the medical marijuana business development and the potential distribution partners within his network for the CBD Hemp products.

The Company has recently identified two (2) reliable and established sources for our private label line of CBD oils, CBD infused products and other supplement formulations. These sources do not require substantial upfront cost and will work with small minimum orders as distribution is developed. As previously announced, we currently have a trial inventory of several products (suggested retail value over $30,000.00). These products include CBD oil, honey, vapes, water enhancers, shampoos, conditioners and body lotions. The sale of this inventory will provide valuable customer feedback, sales and capital for additional inventory.

Mr. Grady’s short term agenda includes:

-The sale of current inventory
-Initial CBD Hemp product line (private label)
- Launch of Company’s ecommerce site (carrying Medically Minded products and other brands)
-Secure an auditor
-Finalize contract and budget with marketing company for product launch

The Company will continue to provide periodic updates to its shareholders as the developments progress forward.

About Cannabidiol (“CBD”) Oil

CBD Rich Hemp Oil is an oil extracted from Industrial Hemp plants (stalks and seeds) with a High Grade of Cannabidiol (CBD). The plants used are specifically and uniquely bred to comprise high concentrations of the naturally occurring Cannabinoid Cannabidiol (CBD). Cannabidiol oil that comes from industrial hemp plants, such as will be the case with our products, are considered by the FDA to be a dietary supplement (not a medication) since they are made from industrial hemp plants.

If you live in the US, this means you don’t need a prescription and can legally purchase and consume Cannabidiol in any state. Cannabidiol from industrial hemp also has the added benefit of having virtually no THC. This is why it’s not possible to get “high” with these products. There simply isn’t enough THC.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program.
FORWARD LOOKING DISCLAIMER: This release contains forward-looking statements that involve risks and uncertainties. Readers are referred to the Securities and Exchange Commission filings filed by the Company on EDGAR at http://www.sec.gov/edgar.shtml, specifically the most recent reports which identify important risk facts that could cause actual results to differ from those contained in the forward-looking statements. The Company undertakes no obligation to review or confirm analysts' expectations or estimates or to publicly release any revisions to any forward-looking statements. The information contained in this press release should not be construed as any indication of the Company's future stock price, its revenues or results of operations.

Contact: INFO@mmusvi.com